Prothena (PRTA) Corporate presentation summary

Mission and disease focus

• Focused on developing life-saving therapies for diseases caused by protein dysregulation, targeting unmet medical needs in neurodegenerative and rare amyloid diseases.

• Addressing major conditions including Parkinson's disease, Alzheimer's disease, and ATTR amyloidosis, impacting millions globally.

Pipeline and technology

• Broad pipeline includes partnered and wholly owned programs, with multiple assets in Phase 3, Phase 2, and preclinical stages.

• Proprietary biology-directed engine enables optimal antibody engineering and epitope mapping for maximal efficacy.

• CYTOPE® technology enables intracellular targeting, expanding therapeutic reach to previously undruggable targets.

Key clinical programs and data

• Prasinezumab (Parkinson's): Phase 3 ongoing; Phase 2 data show delayed motor progression and favorable safety profile.

• Coramitug (ATTR-CM): Phase 3 ongoing; Phase 2 showed significant NT-proBNP reduction and cardiac improvements.

• BMS-986446 (Alzheimer's): Phase 2 ongoing; targets tau MTBR, with preclinical and Phase 1 data supporting efficacy and safety.

• PRX019 (Neurodegeneration): Phase 1 completed; decision on further development expected by end of 2026.

• TDP-43 CYTOPE® (ALS): Preclinical data show reduction of toxic aggregates and correction of RNA splicing defects.

• PRX012-TfR (Alzheimer's): Preclinical; aims for rapid amyloid reduction and lower ARIA risk.